IONS

SEC source: 0000874015-18-000021 · edgar.xml · derivative · entry 3

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,141

Underlying: Common Stock · 12,141 shares

Expires not disclosed

F4 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000021 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000019 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,148

Underlying: Common Stock · 6,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F1 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000019 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,137

Underlying: Common Stock · 12,137 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F1 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F1 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000019 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F2 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000018 · edgar.xml · derivative · entry 9

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,047

Underlying: Common Stock · 1,722 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000018 · edgar.xml · derivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,515

Underlying: Common Stock · 29,612 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000018 · edgar.xml · derivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,911

Underlying: Common Stock · 3,911 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_price: Grant to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000018 · edgar.xml · derivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,149

Underlying: Common Stock · 35,149 shares

Expires not disclosed

F4 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000018 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,128

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.768, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-18-000018 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000018 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,733

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-18-000018 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,626

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 6

Monia Brett P · CIK 0001537529 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,703

Underlying: Common Stock · 6,985 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 5

Monia Brett P · CIK 0001537529 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 4

Monia Brett P · CIK 0001537529 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,916

Underlying: Common Stock · 12,916 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000017 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2025-01-13

F4 · derivative.exercise_date: Grant of 1/14/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/14/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,500 shares per year. Following this transaction, the option was exercisable as to 0 on 1/14/2018.

F4 · derivative.expiration_date: Grant of 1/14/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/14/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,500 shares per year. Following this transaction, the option was exercisable as to 0 on 1/14/2018.

SEC source: 0000874015-18-000012 · edgar.xml · derivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 7,904

Underlying: Common Stock · 1,000 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000012 · edgar.xml · derivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,642

Underlying: Common Stock · 10,000 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000012 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,062

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.67 to $52.35, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-18-000012 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

SEC source: 0000874015-18-000012 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,014

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.67 to $52.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-18-000012 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

SEC source: 0000874015-18-000011 · edgar.xml · derivative · entry 10

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 8,904

Underlying: Common Stock · 1,096 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000011 · edgar.xml · derivative · entry 9

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 0

Underlying: Common Stock · 904 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000011 · edgar.xml · derivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,642

Underlying: Common Stock · 20,000 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,062

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.71 to $50.32, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 5

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,158

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,062

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,014

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.71 to $50.32, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-18-000011 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016.

SEC source: 0000874015-18-000009 · edgar.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,575

Underlying: Common Stock · 103,575 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 25,894 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000008 · edgar.xml · derivative · entry 2

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,638

Underlying: Common Stock · 54,638 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,660 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000007 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,125

Underlying: Common Stock · 58,125 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000007 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,619

F3 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014.

F3 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014.

SEC source: 0000874015-18-000006 · edgar.xml · derivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,619

Underlying: Common Stock · 54,619 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000005 · edgar.xml · derivative · entry 2

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,125

Underlying: Common Stock · 58,125 shares

Expires 2025-01-02

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000004 · edgar.xml · derivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 17,603

Underlying: Common Stock · 17,603 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,401 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000004 · edgar.xml · derivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,175

Underlying: Common Stock · 158,175 shares

Expires 2025-01-02

F1 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 39,544 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000003 · edgar.xml · derivative · entry 2

Boyce Sarah · CIK 0001629383 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,125

Underlying: Common Stock · 58,125 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000002 · edgar.xml · derivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,619

Underlying: Common Stock · 54,619 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000009 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,827

F1 · kind: Reporting 86 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 86 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 86 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 86 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000008 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,486

F1 · kind: Reporting 53 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 53 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 53 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 53 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000007 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,782

F1 · kind: Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000006 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,492

F1 · kind: Reporting 100 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 100 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 100 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 100 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000005 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,671

F1 · kind: Reporting 320 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 320 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 320 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 320 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000003 · edgar.xml · nonDerivative · entry 1

Boyce Sarah · CIK 0001629383 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,760

F1 · kind: Reporting 491 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 491 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 491 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 491 shares may not be sold until July 2, 2018.

SEC source: 0000874015-18-000002 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,147

F1 · kind: Reporting 106 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 106 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 106 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 106 shares may not be sold until July 2, 2018.